• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    IntelGenx Gets US Patent for Montelukast Product

    Bryan Mc Govern
    Dec. 11, 2017 08:30AM PST
    Pharmaceutical Investing

    IntelGenx announced it received a patent allowance from the United States Patent and Trademark Office.

    IntelGenx (TSXV:IGX; OTCQX:IGXT) announced it received a patent allowance from theĀ United States Patent and Trademark Office (USPTO).
    As quoted in the press release:

    This film formulation patent covers Montelukast oral film formulations designed for the treatment of neuroinflammation and is intended to protect IntelGenx’ Montelukast VersaFilmā„¢ product.
    IntelGenx’ new, soon to be patented Montelukast oral film technology is designed to provide increased plasma concentration as compared with an immediate release oral tablet having an identical loading of Montelukast.
    ā€œThe granting of this notice of allowance for a formulation specific orange book eligible patent for our Montelukast oral film validates the innovative work carried out on this project by our talented R&D teamā€ said Horst G. Zerbe, CEO of IntelGenx. ā€œWhile expanding our overall intellectual property portfolio, this new patent also solidifies the potential long-term market exclusivity of our unique Montelukast film product.ā€

    Click here to read the full press release.

    Source: www.marketwired.com

    pharmaceutical investingunited states patent and trademark officeunited states
    The Conversation (0)

    Go Deeper

    AI Powered
    Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

    Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

    Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ɨ